Sugi Predict

Sugi Predict / Compounds / SCHEMBL6490907

SCHEMBL6490907

SCHEMBL6490907

O=C1CC(C(=O)N2CCC(c3ccccc3)CC2)CCc2c(Br)cccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 3/20 0.47
▸ HTR2B P41595 1/20 0.41
▸ MAPK1 P28482 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CCR5 P51681 3/20 0.38
▸ SLC18A3 Q16572 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ SPR P35270 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ SCD5 Q86SK9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6081230 0.89 ADAM10 (0.43) BACE1SMN1; SMN2NPC1
SCHEMBL6499095 0.88 HTR2B (0.44) BACE1HTR2BMAPK1SIGMAR1KCNH2
SCHEMBL6490937 0.88 BACE1 (0.43) BACE1HTR2BMAPK1SIGMAR1CA12
SCHEMBL6499625 0.88 SPR (0.43) BACE1HTR2BMAPK1SIGMAR1KCNH2
SCHEMBL6081678 0.87 RORC (0.41) BACE1
SCHEMBL6499841 0.87 NPC1 (0.42) BACE1HTR2BMAPK1SIGMAR1KCNH2
SCHEMBL6501862 0.87 BACE1 (0.42) BACE1HTR2BMAPK1SIGMAR1KCNH2
SCHEMBL6075908 0.84 KMT2A (0.48) SMN1; SMN2CCR5NPC1
SCHEMBL6493038 0.82 BACE1 (0.46) BACE1HTR2BMAPK1KCNH2HRH3
SCHEMBL6080094 0.82 BACE1 (0.41) BACE1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112250718-B Photoelectric dual-response mercury ion probe and preparation method and application thereof 内蒙古工业大学 2023-02-07 — — CN claimed
CN-112250718-A Photoelectric dual-response mercury ion probe and preparation method and application thereof 内蒙古工业大学 2021-01-22 — — CN claimed
WO-2026107425-A1 5-(PYRIDIN-4-YL)-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE BRISTOL-MYERS SQUIBB COMPANY (US) 2026-05-21 — — WO disclosed
WO-2026107424-A1 N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE BRISTOL-MYERS SQUIBB COMPANY (US) 2026-05-21 — — WO disclosed
CN-115894353-A Synthetic method of 2, 3-diamino-4-bromopyridine 山西永津集团有限公司 2023-04-04 — — CN disclosed
CN-112250718-B Photoelectric dual-response mercury ion probe and preparation method and application thereof 内蒙古工业大学 2023-02-07 — — CN disclosed
CN-112250718-A Photoelectric dual-response mercury ion probe and preparation method and application thereof 内蒙古工业大学 2021-01-22 — — CN disclosed
US-20180273528-A1 IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2018-09-27 — — US disclosed
EP-3356363-A1 NEW IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS DUAL DYRK1/CLK1 INHIBITORS Les Laboratoires Servier (FR) 2018-08-08 — — EP disclosed
US-6969724-B2 Compounds SMITHKLINE BEECHAM-SPA (GB) 2005-11-29 — — US disclosed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 — — US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 — — US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 — — US disclosed
CN-1335847-A Sulfonamide compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO (JP) 2002-02-13 — — CN disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 — — EP disclosed
EP-1129072-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS Smithkline Beecham S.p.A. (IT) 2001-09-05 — — EP disclosed
WO-2000027815-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS SMITHKLINE BEECHAM SPA (IT) 2000-05-18 — — WO disclosed
US-4002761-A ANTHELMINTIC AGENTS, FUNGICIDAL AGENTS SMITHKLINE CORPORATION (US) 1977-01-11 — — US disclosed
US-4000285-A ANTHELMINTICS SMITHKLINE CORPORATION (US) 1976-12-28 — — US disclosed
US-3961063-A ANTHELMINTICS SMITHKLINE CORPORATION (US) 1976-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180273528-A1 IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IDH2, CYP4B1, RB1 BACE1 1009/4885HTR2B 869/4885MAPK1 1090/4885
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A BACE1 1351/4885HTR2B 2339/4885MAPK1 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.